|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM317672444 |
| 003 |
DE-627 |
| 005 |
20250228093153.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.molliq.2020.114734
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1058.xml
|
| 035 |
|
|
|a (DE-627)NLM317672444
|
| 035 |
|
|
|a (NLM)33199930
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ahmad, Sajjad
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A computational study to disclose potential drugs and vaccine ensemble for COVID-19 conundrum
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 16.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a © 2020 Elsevier B.V. All rights reserved.
|
| 520 |
|
|
|a The nucleocapsid (N) protein of SARS-COV-2, a virus responsible for the current COVID-19 pandemic, is considered a potential candidate for the design of new drugs and vaccines. The protein is central to several critical events in virus production, with its highly druggable nature and rich antigenic determinants making it an excellent anti-viral biomolecule. Docking-based virtual screening using the Asinex anti-viral library identified binding of drug molecules at three specific positions: loop 1 region, loop 2 region and β-sheet core pockets, the loop 2 region being the most common binding and stable site for the bulk of the molecules. In parallel, the protein was characterized by vaccine design perspective and harboured three potential B cell-derived T cell epitopes: PINTNSSPD, GVPINTNSS, and DHIGTRNPA. The epitopes are highly antigenic, virulent, non-allergic, non-toxic, bind with good affinity to the highly prevalent DRB*0101 allele and show an average population coverage of 95.04%. A multi-epitope vaccine ensemble which was 83 amino acids long was created. This was highly immunogenic, robust in generating both humoral and cellular immune responses, thermally stable, and had good physicochemical properties that could be easily analyzed in in vivo and in vitro studies. Conformational dynamics of both drug and vaccine ensemble with respect to the receptors are energetically stable, shedding light on favourable conformation and chemical interactions. These facts were validated by subjecting the complexes to relative and absolute binding free energy methods of MMGB/PBSA and WaterSwap. A strong agreement on the system stability was disclosed that supported ligand high affinity potential for the receptors. Collectively, this work sought to provide preliminary experimental data of existing anti-viral drugs as a possible therapy for COVID-19 infections and a new peptide-based vaccine for protection against this pandemic virus
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a COVID-1
|
| 650 |
|
4 |
|a Drugs
|
| 650 |
|
4 |
|a Nucleocapsid (N) protein
|
| 650 |
|
4 |
|a SARS-COV-2
|
| 650 |
|
4 |
|a Vaccine
|
| 700 |
1 |
|
|a Waheed, Yasir
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ismail, Saba
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Abbasi, Sumra Wajid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Najmi, Muzammil Hasan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of molecular liquids
|d 1998
|g 324(2021) vom: 15. Feb., Seite 114734
|w (DE-627)NLM098180800
|x 0167-7322
|7 nnas
|
| 773 |
1 |
8 |
|g volume:324
|g year:2021
|g day:15
|g month:02
|g pages:114734
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.molliq.2020.114734
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 324
|j 2021
|b 15
|c 02
|h 114734
|